<DOC>
	<DOCNO>NCT00001997</DOCNO>
	<brief_summary>To investigate safety polyethylene glycolated interleukin-2 ( PEG IL-2 ) give subcutaneously conjunction antiviral treatment explore effect treatment surrogate marker efficacy incidence opportunistic infection clinical marker HIV disease .</brief_summary>
	<brief_title>Safety Efficacy Polyethylene Glycolated IL-2 ( PEG IL-2 ) Plus Zidovudine Dideoxyinosine HIV Positive , Asymptomatic Symptomatic Individuals</brief_title>
	<detailed_description>Four escalate dos PEG IL-2 study . Patients stratify CD4 level . CD4 level Group A 200 500 cells/mm3 ; Group B - 1 less 200 cells/mm3 . Further stratification p24 positive negative , antiviral therapy less year , zidovudine ( AZT ) versus didanosine ( ddI ) . The duration PEG IL-2 treatment maximum 28 week . This outpatient study ; patient observe four hour first dose PEG IL-2 one hour subsequent dos .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Inclusion Criteria Patients must : HIV seropositivity commercially available ELISA . Meet Disease Status criterion . Exclusion Criteria Coexisting Condition : Patients follow condition symptom exclude : Concurrent neoplasm basal cell carcinoma skin , insitu carcinoma cervix limit cutaneous Kaposi 's sarcoma . Recently treat HIVrelated lymphoma . Major organ allograft . Presence space occupy central nervous system ( CNS ) lesion condition would anticipate cause cerebral edema . Renal compromise use drug therapy anticipate lead renal compromise . Active opportunistic infection require hospitalization exclude medication . Requiring continual acyclovir suppression herpes infection . Concurrent Medication : Excluded : Acyclovir . Drug therapy anticipate lead renal compromise . Patients follow exclude : Intolerance zidovudine ( AZT ) 300 mg/day divide q8h didanosine ( ddI ) 7 mg/kg/day give twice day . History HIVrelated lymphoma . History asthma require frequent therapy , chronic pulmonary disease , hypertension require therapy , congestive heart failure . Any symptoms condition list Exclusion CoExisting Conditions . Prior Medication : Excluded : Any prior therapy interleukin2 ( IL2 ) PEG IL2 . Excluded 30 day prior study entry : Treatment antiHIV medication know immunomodulators chemotherapy radiation therapy . Active substance abuse patient would anticipate poorly compliant protocol requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 1991</verification_date>
	<keyword>Recombinant Proteins</keyword>
	<keyword>Polyethylene Glycols</keyword>
	<keyword>Interleukin-2</keyword>
	<keyword>Didanosine</keyword>
	<keyword>Zidovudine</keyword>
</DOC>